Lintuzumab-Ac225

BIOLOGICAL3 trials

Sponsors

Actinium Pharmaceuticals

Conditions

AMLAcute Myeloid LeukemiaRelapsed Adult AML

Phase 1

Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients

CompletedNCT02575963

Actinium PharmaceuticalsAML

Start: 2012-10-31End: 2020-05-31Updated: 2023-07-20

Venetoclax and Lintuzumab-Ac225 in AML Patients

Actinium PharmaceuticalsAcute Myeloid Leukemia, Relapsed Adult AML

Start: 2020-01-15End: 2024-06-30Target: 38Updated: 2023-08-04

Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

WithdrawnNCT03932318

Actinium PharmaceuticalsAcute Myeloid Leukemia, Relapsed Adult AML

Start: 2023-03-31End: 2024-09-30Updated: 2023-07-20

Related Papers

225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models

Cancer Medicine2020-12-2146 citations